Skip to content

The amnestic effect of Remazolam

Observation of amnestic effect of general anesthesia with Remazolam

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072127
Enrollment
Unknown
Registered
2023-06-04
Start date
2023-05-20
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Observation of amnestic effect of general anesthesia with Remazolam

Interventions

Sponsors

Hefei BOE Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1) Obtain informed consent; 2) Age =20 years, =60 years; 3) Patients who plan to undergo general anesthesia; 4) American Society of Anesthesiologists (ASA) Grade I to III

Exclusion criteria

Exclusion criteria: Exclusion criteria: Any of the following will be excluded from this study 1) Patients with severe heart, brain, lung, liver, kidney and other important organ dysfunction and electrolyte abnormalities before surgery; 2) A history of mental illness or long-term use of psychotropic drugs (dementia, schizophrenia), chronic analgesic drugs, and alcoholism; 3) Patients with a history of intraoperative drug use allergy; 4) Patients with cognitive impairment before surgery were determined by MMSE scale; 5) Patients considered unsuitable for this study by other researchers(YNMT)·

Design outcomes

Primary

MeasureTime frame
Memory of patients at different time points after surgery;

Secondary

MeasureTime frame
Adverse reactions;Total dosage of remimazolam and remifentanil during operation;

Countries

China

Contacts

Public Contactdengrong wei

Hefei BOE Hospital

weidengrong@boe.com.cn+86 130 1936 5599

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026